跳至主要内容
临床试验/NL-OMON50312
NL-OMON50312已完成不适用

Pilot study: Toxicity of oestradiol for adjuvant endocrine therapy in locally confined prostate cancer - OAT - Oestradiol adjuvant trial

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1) Men * 18 years.
  • 2) Locally advanced prostate cancer.
  • 3) Selected for at least two years of adjuvant endocrine therapy and EBRT.
  • 4) Signed informed consent.
  • 5) Testosterone serum level > 6 nmol/l.

排除标准

  • 1) Current endocrine treatment or previous therapy within 6 months (5-alpha
  • reductase inhibitors are permitted).
  • 2) Previous radiological confirmed deep venous thrombosis or pulmonary embolus.
  • 3) Cerebrovascular event (TIA or CVA) within 6 months.
  • 4) Coronary heart disease within 6 months.
  • 5) Instable angina pectoris within 6 months.
  • 6) Congenital thrombofilic diseases.
  • 7) Thrombolic disease within 6 months.
  • 8) Heart failure as defined by NYHA class >2.
  • 9) Hypertension (not corrected by medication) >160/100 mmHg. If either systolic
  • or diastolic value is higher than these values the patient is not eligible.
  • 10) Suboptimal regulated diabetes mellitus or de novo diabetes mellitus as
  • defined by HbA1c of over 6,5% (48 mmol/mol).
  • 11) Rheumatoid arthritis.
  • 12) Impaired renal function as defined by a GFR < 30 ml/ min/1,73 m2
  • 13) Acute liver failure or reduced liver function showing as increased serum
  • parameters (SGOT, SGPT, bilirubine > 2.5 times normal).
  • 14) Porfyria.

研究者

相似试验